GlassScriptPhysician profile
Colleen A Devinney
NPI 1518923481
$1,760.97
in general payments reported to CMS, 2019-2025
26 companies · $616 in 2025
The $616 reported for 2025 was more than what 77% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $271 · 2020: $102 · 2021: $67.84 · 2022: $15.87 · 2023: $189 · 2024: $498 · 2025: $616.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $274.22 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $270.69 | 2019-2025 | Wegovy |
| Abbvie INC. | $180.39 | 2019-2025 | Rinvoq |
| Pfizer INC. | $148.04 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $116.94 | 2019-2025 | Airsupra, Breztri |
| Sanofi Pasteur INC. | $111.73 | 2019-2024 | |
| Welch Allyn | $99.13 | 2020-2021 | |
| Dexcom, INC. | $74.52 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $73.05 | 2024 | Inspire |
| Axsome Therapeutics, INC. | $45.69 | 2025 | Auvelity |
| Exact Sciences Corporation | $39.18 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $37.87 | 2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Boston Scientific Corporation | $29.76 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $29.23 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Alexion Pharmaceuticals, INC. | $27.71 | 2024 | Ultomiris |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $25.56 | 2025 | Skyclarys |
| Astellas Pharma US INC | $25.22 | 2024 | Veozah |
| Actelion Pharmaceuticals US, INC. | $24.95 | 2025 | Opsumit, Uptravi |
| Abbott Laboratories | $21.73 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $20.51 | 2020 | |
| Shield Therapeutics INC | $19.65 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.27 | 2025 | Zoryve |
| Idorsia Pharmaceuticals US INC | $14.16 | 2023 | Quviviq |
| Bausch Health US, LLC | $11.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colleen Devinney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.